22 March 2021 | News
Eisai begins construction of new injection building and research building at Kawashima Koen
Photo Credit: Freepik
Japanese firm Eisai Co., Ltd. as part of its strategic investment to realize its medium-term management plan, EWAY 2025. , Kawashima Koen (Gifu Prefecture) has announced that the groundbreaking ceremony for the construction of the new injection building/research building (Eisai Medicine Innovation Technology Solutions or EMITS) has been held.
Since its completion in 1980, the current research building of Kawashima Koen has been in charge of research on the formulation of in-house created drugs. In addition to conventional small molecules, drug discovery targets are expanding to new modalities such as antibodies, antibody-drug conjugates (ADCs), and nucleic acids. Most of the new modality is injectables, and it is even more important to strengthen the formulation technology of injectables and utilize drug delivery technology (DDS).
At EMITS, in order to expand support for these new modality formulations, Eisai will transfer the formulation research function from the current research building and strengthen the injection manufacturing process development function. In addition, it will introduce an injection manufacturing facility that meets GMP requirements for the in-house manufacture of investigational drugs for injections.
In addition, Eisai plans to introduce a system that supports the development of cutting-edge formulation technologies such as liposomes and lipid nanoparticle formulations and to set up an experimental space where joint research with outside parties is possible.
Through these efforts, Eisai aim to improve the technological capabilities and knowledge of formulation research functions and become a base for transmitting innovations, technologies, and solutions related to formulations. Completion is scheduled for the second quarter of 2022.
Kawashima Koen is Eisai's global manufacturing base for pharmaceutical products and has built a comprehensive system from formulation research to formulation manufacturing. Through the construction of EMITS.